Effect of Pitavastatin Treatment on ApoB-48 and Lp-PLA in Patients with Metabolic Syndrome: Substudy of PROspective Comparative Clinical Study Evaluating the Efficacy and Safety of PITavastatin in Patients with Metabolic Syndrome
BackgroundApolipoprotein (Apo) B-48 is an intestinally derived lipoprotein that is expected to be a marker for cardiovascular disease (CVD). Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a vascular-specific inflammatory marker and important risk predictor of CVD. The aim of this study was to...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Endocrine Society
2016-03-01
|
Series: | Endocrinology and Metabolism |
Subjects: | |
Online Access: | http://e-enm.org/Synapse/Data/PDFData/2008ENM/enm-31-120.pdf |